Benzinga | Nov 17, 2021 10:03AM EST

Cytek Biosciences Reports Has Shipped 1K Of Its Cell Analysis Systems

Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced a significant milestone: the company has shipped 1,000 of its cell analysis systems. Since first being introduced in 2017, Cytek's cell analysis systems have gained widespread adoption across the globe with use in more than 35 countries. Utilizing Cytek's patented Full Spectrum Profiling(tm) (FSP(tm)) technology, Cytek provides an integrated suite of solutions with its Aurora and Northern Lights(tm) systems, Aurora CS cell sorter, reagents, software and services.

To provide researchers with a more comprehensive understanding of the human immune system, Cytek has broadened its product portfolio. Earlier this year, Cytek introduced a new high-dimensional sorter to deliver high-resolution capabilities at the single cell level to resolve and sort even the most challenging cell populations. The company also released a 14-color immunoprofiling kit and a 25-color immunoprofiling assay and recently acquired Tonbo Biosciences'(tm) portfolio of reagents to complement Cytek's cFluor(r) family of proprietary reagents.

"The shipment of our 1000th instrument marks a significant milestone in our company's history," noted Dr. Wenbin Jiang, CEO of Cytek Biosciences. "From the outset, our mission has been to advance the scope, reach and capabilities of flow cytometry -- to provide researchers around the globe with the solutions they need to improve patient treatments and outcomes. Today, we are a full cell analysis solutions company -- from analyzers to sorters, reagent kits, assays and more -- all of which provide deeper insights and understanding of biological systems to accelerate the pace of discovery. We're proud to have earned the trust of the scientific community."

Cytek closed on its IPO in July 2021, taking the company to new heights. To support Cytek's growth and expanded product portfolio, the company has invested in additional infrastructure, with new offices in the United States (Fremont, California; Seattle, Washington) and the European Union (Amsterdam, Netherlands).

The company's achievements are reflected in more than 300 noted peer-reviewed journals in which Cytek solutions were utilized in research ranging from immuno-oncology to infectious diseases to inflammatory diseases. Citations for these publications can be accessed at https://cytekbio.com/blogs/publications.

Added Jiang, "As we look ahead to 2022 and beyond, we are excited for the future of Cytek -- and will remain committed to adapting our technology to meet the needs of our users so they can solve even the most complex research questions."

For more information about Cytek, please visit www.cytekbio.com.